Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Beta-maltose
2. 69-79-4
3. 133-99-3
4. D-maltose
5. Maltobiose
6. D-(+)-maltose
7. 4-o-alpha-d-glucopyranosyl-beta-d-glucopyranose
8. Cextromaltose
9. Finetose
10. Maltodiose
11. Sunmalt
12. Malt Sugar
13. Finetose F
14. Sunmalt S
15. Cellobiose
16. R4b6462ngr
17. Insulin, (arg-insulin)
18. Maltose, Pure
19. Chebi:18147
20. Beta-d-cellobiose
21. Beta-d-glucopyranose, 4-o-alpha-d-glucopyranosyl-
22. 4-o-alpha-d-glucopyranosyl-d-glucose
23. Nsc-760396
24. (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
25. 120022-04-0
26. Beta-d-glucopyranosyl(1-4)-d-glucopyranose
27. 4-(alpha-d-glucosido)-d-glucose
28. 4-(alpha-d-glucopyranosido)-alpha-glucopyranose
29. D-glucose, 4-o-alpha-d-glucopyranosyl-
30. B-d-glucopyranose, 4-o-a-d-glucopyranosyl-
31. Alpha-d-glucopyranosyl-(1->4)-beta-d-glucopyranose
32. Ai3-09089
33. Maltose Anhydrous
34. Maltose Hh
35. Maltose Hhh
36. Advantose 100
37. Beta-d-maltose
38. Maltose, Beta-
39. (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-(((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hexanal
40. Maltose Beta-anomer
41. Unii-r4b6462ngr
42. Maltroise
43. 1wdr
44. N9s
45. Glca1-4glcb
46. Glcalpha1-4glcbeta
47. Maltose (8ci)
48. Sunmalt-s
49. 2f5t
50. .beta.-maltose
51. Maltose, Unspecified Form
52. .beta.-d-maltose
53. .beta.-d-cellobiose
54. Schembl15064
55. Maltose .beta.-anomer
56. .beta.-d-glucopyranose, 4-o-.alpha.-d-glucopyranosyl-
57. Chembl1908365
58. Dtxsid901318570
59. Hms3264c14
60. Pharmakon1600-01301024
61. Zinc4095762
62. Mfcd00079443
63. Nsc760396
64. Alpha-d-glcp-(1->4)-beta-d-glcp
65. Ccg-231520
66. Ncgc00389762-01
67. Bs-10031
68. C01971
69. D70315
70. 4-o-(alpha-d-glucopyranosyl)-beta-d-glucopyranose
71. Alpha-d-glucopyranose-(1->4)-beta-d-glucopyranose
72. 857a38d2-86d7-41f1-bc3c-dadbc19cf9dc
73. D-glucose, 4-o-alpha-d-glucopyranosyl- (6ci,9ci)
74. Q26914030
75. Wurcs=2.0/2,2,1/[a2122h-1b_1-5][a2122h-1a_1-5]/1-2/a4-b1
76. (2r,3s,4s,5r,6r)-2-methylol-6-[(2r,3s,4r,5r,6r)-4,5,6-trihydroxy-2-methylol-tetrahydropyran-3-yl]oxy-tetrahydropyran-3,4,5-triol
| Molecular Weight | 342.30 g/mol |
|---|---|
| Molecular Formula | C12H22O11 |
| XLogP3 | -4.7 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 4 |
| Exact Mass | 342.11621151 g/mol |
| Monoisotopic Mass | 342.11621151 g/mol |
| Topological Polar Surface Area | 190 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 382 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Sweetening Agents
Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (From Random House Unabridged Dictionary, 2d ed) (See all compounds classified as Sweetening Agents.)
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18162
Submission : 2005-03-11
Status : Inactive
Type : IV



FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18162
Submission : 2005-03-11
Status : Inactive
Type : IV

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.
About the Company : Pfanstiehl is a leader in high-purity, low endotoxin, low metals parenteral-grade excipient manufacturing for biologic formulations. The company’s expertise includes isolation, p...
About the Company : DRRPSL (Dr. Raju’s Pharma Solutions, LLC.) a New Jersey-based Corporation, is actively involved in the support of Developing New Drugs and Their Commercialization for both the In...

About the Company : Sukhjit came into existence when two astute young entrepreneurs recognized the vast potential of the versatile grain "MAIZE" and decided to establish a Corn Wet Milling Facility.Su...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.
Lead Product(s): Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Probiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Scioto Biosciences Announces Publication of Phase 1b Study in Autism
Details : SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.
Lead Product(s): Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Probiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lactobacillus Reuteri,Maltose,Sephadex
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Top-line results from the study demonstrated that SB-121 (Lactobacillus Reuteri), represents the first clinical validation of ABT platform was safe and well tolerated.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
May 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
APS001F is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): APS001F,Fluocytosine,Maltose
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APS001F,Fluocytosine,Maltose
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Details : APS001F is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 26, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
REF. STANDARDS & IMPURITIES
Monograph in Japanese Pharmacopoeia : Maltose Hy...
Package Size : 300 mg
Price (¥) : 33,553
Storage Temperature °C : 25°C
Assay Test : A/ LC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
CAS Number : 6363-53-7
Quantity Per Vial :
Sale Unit :
Price : $122.00
Details :
Monograph : PHR1497-1G
Storage : +2°C to +30°C
Code/Batch No :
CAS Number : 6363-53-7
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : M0050.00

CAS Number :
Quantity Per Vial :
Sale Unit :
Price : $122.00
Details :
Monograph : PHR1497-1G
Storage : +2?C to +30?C
Code/Batch No :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
10
PharmaCompass offers a list of Maltose API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Maltose manufacturer or Maltose supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Maltose manufacturer or Maltose supplier.
A Sunmalt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sunmalt, including repackagers and relabelers. The FDA regulates Sunmalt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sunmalt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sunmalt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Sunmalt supplier is an individual or a company that provides Sunmalt active pharmaceutical ingredient (API) or Sunmalt finished formulations upon request. The Sunmalt suppliers may include Sunmalt API manufacturers, exporters, distributors and traders.
click here to find a list of Sunmalt suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Sunmalt DMF (Drug Master File) is a document detailing the whole manufacturing process of Sunmalt active pharmaceutical ingredient (API) in detail. Different forms of Sunmalt DMFs exist exist since differing nations have different regulations, such as Sunmalt USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sunmalt DMF submitted to regulatory agencies in the US is known as a USDMF. Sunmalt USDMF includes data on Sunmalt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sunmalt USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sunmalt suppliers with USDMF on PharmaCompass.
Sunmalt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sunmalt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sunmalt GMP manufacturer or Sunmalt GMP API supplier for your needs.
A Sunmalt CoA (Certificate of Analysis) is a formal document that attests to Sunmalt's compliance with Sunmalt specifications and serves as a tool for batch-level quality control.
Sunmalt CoA mostly includes findings from lab analyses of a specific batch. For each Sunmalt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sunmalt may be tested according to a variety of international standards, such as European Pharmacopoeia (Sunmalt EP), Sunmalt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sunmalt USP).